Browse the evidence

Pharmacological activation of brown and beige adipose tissue thermogenesis via beta-3 adrenergic signaling or UCP1-independent futile cycles increases energy expenditure and improves systemic metabolic health.

Your fat tissue is not just storage; it actively regulates your metabolism. While cold exposure can activate brown fat, current medical strategies focus on pharmacological agents (like GLP-1 agonists) that may indirectly support metabolic health. Understanding that visceral fat is metabolically harmful while subcutaneous fat is more neutral can guide lifestyle choices, but surgical removal of fat is not a cure for metabolic disease.

Replacing saturated fatty acids with omega-6 polyunsaturated fatty acids has a neutral effect on blood pressure.

Switching from saturated fats to omega-6 oils will not significantly lower your blood pressure. If blood pressure management is your primary goal, other dietary strategies (like reducing sodium or increasing potassium) may be more effective, though this substitution still benefits cholesterol levels.

A low-fat diet intervention (targeting 20% of calories from fat) does not reduce the incidence of coronary heart disease, stroke, or type 2 diabetes compared to a control group with minimal dietary guidance.

Do not rely on a low-fat diet as a primary strategy for preventing heart disease or diabetes. Simply reducing fat to 20% without improving the quality of the remaining calories (e.g., replacing with refined carbs) does not improve outcomes.

Premenopausal women exhibit sex-specific fat distribution characterized by preferential subcutaneous adipose tissue (SAT) storage and higher brown adipose tissue (BAT) activity, which provides metabolic protection against visceral obesity and cardiovascular disease compared to men.

If you are a premenopausal woman, your body naturally stores fat in your hips and thighs (subcutaneous) rather than around your organs (visceral), and you likely have more active brown fat for energy burning. This is a biological advantage for metabolic health. Do not equate higher total body fat with higher health risk compared to men; your distribution pattern is protective.

Supplementing with whey protein, soy protein, or isolated leucine (standardized to ~3g leucine per serving) provides no additional benefit for increasing skeletal muscle mass or strength compared to a placebo when combined with resistance training in previously untrained college-aged males who already consume adequate protein (>1.3 g/kg/day) and increase caloric intake.

If you are a beginner lifter eating enough protein (over 1.3g/kg/day) and eating enough calories to support training, you do not need to spend extra money on whey, soy, or leucine supplements. They will not help you build more muscle or strength compared to a placebo, as long as your total diet is sufficient. Focus on your training and total food intake first.

High baseline plasma levels of specific advanced glycation end products (G-H1) and oxidation products (2-AAA) are strongly associated with greater severity of subclinical atherosclerosis (measured by CIMT, CAC, and AAC) over a 10-year follow-up in patients with type 2 diabetes.

For people with type 2 diabetes, maintaining good blood sugar control early and consistently is crucial because high blood sugar creates lasting chemical byproducts (AGEs and OxPs) that damage blood vessels for years, even after glucose levels are normalized. This damage contributes to heart disease risk long-term, highlighting the importance of early intervention and sustained management rather than just recent control.

Coronary Microvascular Dysfunction (CMD) is a significant predictor of adverse cardiovascular events, heart failure with preserved ejection fraction (HFpEF), and mortality in diabetic patients, even in the absence of obstructive coronary artery disease.

Normal results on a standard angiogram (looking for big blockages) do not guarantee heart health if you have diabetes. Microvascular dysfunction can still cause heart failure and heart attacks. Monitoring for symptoms like shortness of breath and chest pain is crucial, as these may signal microvascular issues.

Long-term elevated plasma TMAO levels are associated with a higher risk of incident atherosclerotic cardiovascular disease (ASCVD), but this association is significantly modified by renal function, being present only in individuals with impaired renal function (eGFR <60 mL/min/1.73 m2).

If you have impaired kidney function (eGFR <60), high TMAO levels are a significant warning sign for heart disease risk. If your kidney function is normal, high TMAO levels may not carry the same risk. Focus on maintaining kidney health and discussing TMAO testing with your doctor if you have known renal impairment.

Elevated plasma TMAO levels are associated with a higher risk of recurrent ASCVD in individuals with preexisting cardiovascular disease, independent of renal function status.

If you have a history of heart disease, higher TMAO levels are linked to a higher risk of another heart event. This risk exists regardless of your kidney function. Discussing TMAO levels with your cardiologist may help tailor your prevention strategy.

Replacing sugar-sweetened beverages (SSBs) with unsweetened beverages (USBs) or artificially sweetened beverages (ASBs) for 12 months does not significantly improve cardiometabolic risk factors (specifically the TG:HDL-C ratio) in the general adult population.

If you drink sugary beverages daily, switching to water or diet soda for a year won't necessarily fix your cholesterol or triglyceride ratios on its own. However, if you carry excess weight around your midsection, switching to either water or diet soda can help you lose weight compared to continuing sugary drinks. Water is better if you want to reduce your craving for sweet tastes.

Counter-regulatory mechanisms, specifically adaptive thermogenesis and increased eating drive, are potent physiological responses to weight loss that actively promote weight regain, thereby limiting the long-term efficacy of lifestyle interventions and pharmacotherapies.

When you lose weight, your body fights back by lowering your metabolic rate and increasing hunger. This is a normal biological response, not a personal failure. To maintain weight loss, you must anticipate this metabolic adaptation and likely require ongoing, structured support rather than relying on initial willpower alone.

Bariatric surgery achieves superior long-term weight loss compared to lifestyle interventions, but this comes with complex physiological changes including transient decreases in resting metabolic rate per fat-free mass and alterations in gut peptides like GLP-1 and PYY.

Bariatric surgery is currently the most effective long-term treatment for obesity, achieving ~25% weight loss. However, it works through complex hormonal changes (like increased GLP-1) and metabolic adaptations, not just stomach size reduction. It requires lifelong medical monitoring.

Skeletal muscle transcriptomic profiling, specifically focusing on a core set of 332 insulin-sensitive genes (CORE-IS) and non-coding RNAs, provides a robust molecular signature for metabolic disease that correlates with genetic loci identified by GWAS and responds to clinical interventions.

This research does not offer a direct lifestyle or supplement intervention. Instead, it highlights that current genetic testing (GWAS) is insufficient for predicting metabolic disease risk without functional data. It suggests that future diagnostics may rely on gene expression profiles (transcriptomics) from muscle tissue to accurately assess insulin sensitivity and metabolic health, potentially guiding personalized treatment strategies for type 2 diabetes and obesity.

Cardiovascular polypills (low-dose combinations of BP, lipid, and anti-thrombotic drugs) may serve as a partial exercise mimetic for cardiovascular risk reduction, though they do not fully replicate exercise's protective mechanisms.

If you cannot exercise, a cardiovascular polypill (combining low-dose BP, lipid, and anti-clotting meds) is a viable, evidence-based strategy to reduce cardiovascular risk. It is not a perfect substitute for exercise but offers significant protection with good adherence rates.

Higher circulating levels of very-long-chain saturated fatty acids (VLSFAs), specifically lignoceric acid (24:0), behenic acid (22:0), and arachidic acid (20:0), are associated with a lower risk of incident heart failure in older adults.

For older adults, maintaining higher levels of very-long-chain saturated fatty acids (like 24:0, 22:0, and 20:0) in the blood is linked to a lower risk of developing heart failure. These fatty acids come from both diet (e.g., peanuts, macadamia nuts, canola oil) and the body's own metabolism. While this doesn't mean you should aggressively supplement saturated fats, it suggests that a diet including these specific fatty acids may be protective. Focus on whole food sources like nuts and seeds rather than processed fats.

GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary disorders, particularly at higher doses and longer treatment durations.

Be aware that GLP-1 medications can slightly increase your risk of gallbladder issues, such as gallstones or inflammation. This risk is higher if you take higher doses or use the medication for a long time. While the absolute risk is low, report any severe abdominal pain to your doctor promptly.

Obesity alters the pharmacokinetics of drugs, affecting absorption, distribution, metabolism, and excretion, which may necessitate dose adjustments for certain medications.

If you have obesity, tell your doctor about all medications you take. Your body may process drugs differently, requiring dose adjustments for safety and effectiveness, especially for drugs metabolized by the liver or kidneys.

Obesity induces chronic low-grade inflammation (LGCI) via adipose tissue hypertrophy, immune cell infiltration (M1 macrophages), and cytokine release (TNF-α, IL-6, IL-1β), which disrupts insulin signaling through JNK and NF-κB pathways, leading to systemic insulin resistance and metabolic dysfunction.

If you have obesity, your body is likely in a state of chronic, low-grade inflammation that actively works against your metabolic health. This isn't just 'being fat'; it's a biological state that disrupts how your body handles insulin and energy. Addressing this inflammation through lifestyle changes (diet, exercise) or medical interventions is crucial for breaking the cycle of metabolic dysfunction.

Global Positioning Systems (GPS) and metabolic power calculations tend to underestimate energy expenditure during soccer match-play compared to indirect calorimetry, particularly during recovery phases.

Be cautious when using GPS devices to estimate calorie burn. They often underestimate energy expenditure, especially during rest periods in soccer. Use this data as a rough guide rather than an exact number when planning nutrition.

Tirzepatide slows the rate of eGFR decline in patients with type 2 diabetes, including those with preserved kidney function (eGFR >60 mL/min/1.73 m2) and normoalbuminuria.

Even if your kidney function tests are currently normal, tirzepatide can help protect your kidneys from future decline. Clinical data shows that this medication slows the rate of kidney function loss compared to insulin, regardless of whether you currently have signs of kidney disease. This makes it a valuable preventive tool for long-term kidney health in people with type 2 diabetes.

Oral branched-chain amino acid (BCAA) supplementation provides negligible benefits for athletic performance and body composition in trained athletes, regardless of supplementation duration or dosage.

If you are an athlete, stop spending money on BCAA supplements for performance or muscle gain. The evidence shows they provide negligible benefits over a normal diet. Ensure you are eating enough total protein daily instead. BCAAs might help slightly with muscle soreness after heavy resistance training, but this is not a guaranteed or significant benefit for most people.

Roux-en-Y gastric bypass (RYGB) surgery restores gut hormone balance by elevating postprandial GLP-1 and PYY levels, which contributes to sustained weight loss and improved glucose homeostasis.

For patients who have undergone Roux-en-Y gastric bypass, the surgery works largely by changing how gut hormones signal fullness (GLP-1 and PYY). This hormonal shift helps maintain weight loss and improves blood sugar control long-term. If surgery is not an option, new combination drug therapies aim to replicate this hormonal effect.

In strength-trained individuals, acute carbohydrate intake does not improve resistance training performance (repetitions to failure or total volume) when compared to a fed state with a 2-5 hour post-prandial window, provided the workout volume is moderate (≤10 sets per muscle group).

If you eat a normal meal 2-5 hours before lifting, you do not need to force-feed yourself carbohydrates right before training to get better reps or strength. Your muscles have enough glycogen. Save the carbs for post-workout or general daily intake. If you train fasted or do extremely high volume (>10 sets/muscle), then carbs may help, but for standard sessions, don't stress about pre-workout carbs.

Long-term carbohydrate manipulation (weeks to months) does not influence strength gains or hypertrophy in strength-trained individuals, provided total caloric and protein intake are adequate.

You do not need to eat a high-carbohydrate diet to build muscle or get strong. Focus on hitting your protein targets and maintaining a caloric surplus (if bulking) or deficit (if cutting). You can choose your carbohydrate intake based on preference, activity level, or metabolic health without sacrificing strength gains.